Contribute Try STAT+ Today

Rise and shine, another busy day is on the way. We can tell because our short person is, once again, hunched over a laptop for a day of learning and our official mascot is perched by a window waiting for a friend to arrive in what feels like an endless parade of doggie playdates. As for us, we are doing the usual thing — brewing cups of stimulation. Our choice today is vanilla caramel cream. One can never be too sweet, yes? Meanwhile, here are a few items of interest for you. Hope your day goes well and you stay safe. …

The U.K.  is seeking constructive engagement with the U.S. and other World Trade Organization members on the issue of intellectual property waivers for Covid-19 vaccines, Reuters reports. The Biden administration last week threw its support behind waiving intellectual property rights for the vaccines, in a sharp reversal of the previous U.S. position. The U.K. has not joined the U.S. in its position, and a U.K. government spokesman suggested that a waiver alone would not be sufficient to help the situation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.